Don't forget about that important patent awarded to Zalicus last April. Good to the year 2032.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has been granted a patent by the U.S. Patent and Trademark office (USPTO) covering novel formulations of its product candidate Z160. United States patent number 8,409,560, entitled “Solid Dispersion Formulations and Methods of Use Thereof,” provides broad coverage for a range of novel Z160 pharmaceutical compositions and methods of using these compositions in the treatment of pain.
“We are delighted to have been issued this important patent extending Z160’s patent protection and exclusivity into 2032”
“We are delighted to have been issued this important patent extending Z160’s patent protection and exclusivity into 2032,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “Solid dispersion technology is well-characterized and has been utilized in a number of commercial and late-stage development products. Building on this knowledge, Zalicus has developed solid dispersion formulations of Z160 that have uniquely improved its bioavailability and have facilitated its advancement into two ongoing Phase 2a clinical trials in chronic neuropathic pain.”